Enovis CORP ENOV
Enovis Corporation (the "Company", "Enovis", "we" or "us") is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion. We seek to leverage our Enovis Growth Excellence business system ("EGX"), a set of tools, processes, and culture, to continuously improve our ability to enable great patient outcomes and to drive and fuel growth.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.25B | $2.11B | $1.71B | $1.56B | $1.43B | $1.12B | $3.33B | $2.19B | $1.94B | $3.19B |
| Cost of revenue | $902.8M | $926.9M | $716.4M | $693.7M | $648.5M | $517.1M | $1.93B | $1.46B | $1.27B | $2.19B |
| Gross profit | $1.35B | $1.18B | $990.8M | $869.4M | $777.7M | $603.6M | $1.40B | $729.4M | $671.6M | $992.4M |
| R&D | $120.3M | $91.3M | $75.3M | $60.8M | $49.1M | $34.3M | — | — | — | — |
| SG&A | $1.07B | $1.03B | $830.3M | $772.9M | $665.8M | $515.5M | $1.13B | $548.8M | $500.6M | $696.8M |
| Operating income | -$1.12B | -$775.7M | -$65.7M | -$71.2M | -$62.8M | -$66.2M | $203.6M | $151.5M | $135.6M | $236.8M |
| Interest expense | $34.8M | $57.1M | $19.7M | $24.1M | $29.1M | $52.8M | $119.5M | $49.1M | $40.1M | $30.3M |
| Pre-tax income | -$1.16B | -$822.9M | -$67.1M | -$2.1M | -$121.8M | -$119.0M | $50.5M | $92.4M | $48.6M | $206.5M |
| Income tax | $22.3M | $4.5M | $13.3M | $36.1M | $19.5M | $44.6M | $31.6M | $29.5M | $2.5M | $51.8M |
| Net income | -$1.18B | -$825.5M | -$33.3M | -$13.3M | $71.7M | $42.6M | -$527.6M | $140.2M | $151.1M | $128.1M |
| EPS, basic | -20.75 | -14.93 | -0.61 | -0.25 | 1.40 | 0.93 | -3.89 | 1.17 | 1.23 | 1.04 |
| EPS, diluted | -20.75 | -14.93 | -0.61 | -0.25 | 1.40 | 0.93 | -3.89 | 1.16 | 1.22 | 1.04 |
| Shares, diluted (wtd. avg.) | $57.1M | $55.3M | $54.5M | $54.1M | $51.1M | $45.6M | $136.7M | $120.8M | $124.0M | $123.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $36.4M | $48.2M | $36.2M | $24.3M | $680.3M | $97.1M | $109.6M | $77.2M | $262.0M | $208.8M |
| Short-term investments | — | — | — | — | — | — | — | — | $149.6M | $0 |
| Receivables | $442.8M | $407.0M | $291.5M | $267.4M | $255.0M | $517.0M | $561.9M | $386.6M | $970.2M | $838.8M |
| Inventory | $584.4M | $547.1M | $468.8M | $426.6M | $356.2M | $564.8M | $571.6M | $359.7M | $429.6M | $365.0M |
| Total current assets | $1.21B | $1.15B | $896.5M | $795.0M | $2.30B | $1.36B | $1.40B | $1.96B | $2.07B | $1.74B |
| Property, plant and equipment | $507.1M | $404.5M | $270.8M | $236.7M | $235.1M | $487.0M | $491.2M | $327.2M | $552.8M | $505.4M |
| Goodwill | $718.3M | $1.69B | $2.06B | $1.98B | $92.4M | $1.76B | $3.20B | $1.50B | $1.43B | $2.35B |
| Other intangibles | $1.24B | $1.32B | $1.13B | $1.11B | $1.15B | $1.66B | $1.72B | $628.3M | $1.02B | $916.3M |
| Total assets | $3.83B | $4.72B | $4.51B | $4.27B | $8.52B | $7.35B | $7.39B | $6.62B | $6.71B | $6.34B |
| Accounts payable | $187.5M | $179.1M | $132.5M | $135.6M | $155.2M | $330.3M | $359.8M | $291.2M | $587.1M | $515.5M |
| Short-term debt | $35.0M | $20.0M | $0 | $219.3M | $7.7M | $27.1M | $27.6M | $5.0M | $5.8M | $5.4M |
| Total current liabilities | $598.5M | $529.0M | $369.6M | $565.2M | $1.02B | $811.7M | $857.3M | $1.20B | $1.10B | $1.06B |
| Long-term debt | $1.26B | $1.31B | $466.2M | $40.0M | $2.08B | $2.20B | $2.28B | $1.19B | $1.06B | $1.29B |
| Total liabilities | $2.34B | $2.15B | $1.09B | $823.4M | $3.85B | $3.76B | $3.90B | $3.14B | $2.98B | $3.25B |
| Retained earnings | -$1.47B | -$283.0M | $542.5M | $575.7M | $589.0M | $517.4M | $479.6M | $991.8M | $846.5M | $685.4M |
| Total equity | $1.49B | $2.56B | $3.42B | $3.45B | $4.66B | $3.59B | $3.49B | $3.48B | $3.73B | $3.09B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $217.3M | $113.5M | $135.0M | -$55.9M | $356.1M | $301.9M | $130.9M | $226.4M | $218.8M | $247.0M |
| Depreciation and amortisation | $1.34B | $927.8M | $217.1M | $203.0M | $187.0M | $167.9M | $215.6M | $81.2M | $72.7M | $128.8M |
| Stock-based compensation | $32.9M | $29.7M | $34.1M | $39.0M | $35.4M | $28.9M | $22.0M | $25.1M | $21.5M | $19.0M |
| Capital expenditure | $197.4M | $180.7M | $122.2M | $105.5M | $104.2M | $114.8M | $125.4M | $69.6M | $68.8M | $63.3M |
| Investing cash flow | -$179.4M | -$955.5M | -$242.5M | -$176.4M | -$320.5M | -$175.1M | -$1.63B | -$167.9M | $89.9M | -$82.0M |
| Financing cash flow | -$52.4M | $846.8M | $127.8M | -$465.1M | $584.9M | -$131.7M | $1.37B | -$47.2M | -$280.4M | -$145.2M |
| Buybacks | $3.5M | $4.8M | $0 | $0 | — | $0 | $0 | $200.0M | $0 | $20.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001420800-26-000012.
Others in SIC 3842
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $129.55B | 46.6x | 20.5% |
| EW | Edwards Lifesciences Corp | $51.82B | 49.1x | 11.5% |
| STE | STERIS plc | $21.90B | 28.3x | 8.7% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $18.71B | 27.6x | 7.2% |
| ALGN | ALIGN TECHNOLOGY INC | $11.27B | 28.1x | 0.9% |
| MSA | MSA Safety Inc | $7.28B | 26.6x | 3.7% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $2.21B | — | 27.1% |
| CDRE | Cadre Holdings, Inc. | $1.27B | 29.2x | 7.5% |